CytomX Therapeutics, Inc. Restructuring Reserve
CytomX Therapeutics, Inc. (CTMX) had Restructuring Reserve of $24.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Balance Sheet › Liabilities
us-gaap:RestructuringReserve · last filed 2026-03-16
- 2025-12-31: Restructuring Reserve $24.00K.
- 2025-09-30: Restructuring Reserve $86.00K.
- 2025-06-30: Restructuring Reserve $161.00K.
- 2025-03-31: Restructuring Reserve $855.00K.
| Period end | Restructuring Reserve |
|---|---|
| 2025-12-31 | $24.00K 10-K · filed 2026-03-16 |
| 2025-09-30 | $86.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $161.00K 10-Q · filed 2025-11-06 |
| 2025-03-31 | $855.00K 10-Q · filed 2025-11-06 |
| 2023-12-31 | $0.00 10-K · filed 2024-03-11 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-07 |
| 2023-06-30 | $30.00K 10-Q · filed 2023-08-08 |
| 2023-03-31 | $83.00K 10-Q · filed 2023-05-09 |
| 2022-12-31 | $1.68M 10-K · filed 2024-03-11 |
| 2022-09-30 | $3.88M 10-Q · filed 2022-11-08 |
| 2021-12-31 | $0.00 10-Q · filed 2022-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |